Chinook Therapeutics Acquisition Finalizes Novartis Expansion into Kidney Disease Market
Published on 11/25/2025 at 15:42 | Redaktion boerse-global.de
The independent trading journey of Chinook Therapeutics shares has concluded. In a strategic move finalized in August 2023, the biotechnology firm was fully acquired by pharmaceutical giant Novartis. Shareholders of the former company received a cash payment of $40 per share, marking the end of Chinook’s tenure as a publicly traded entity.
The acquisition was driven by Novartis’s strategic objective to bolster its presence in the nephrology treatment sector. Chinook’s valuable pipeline, featuring late-stage development products for rare kidney conditions, presented a compelling opportunity. The boards of directors from both organizations gave their unanimous approval for the transaction.
Under the terms of the agreement, Novartis completed the purchase Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
